Avalo Therapeutics, Inc.
AVTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534120
In the last 90 days, Avalo Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $1.31B in total; no superinvestor holds it.
Q1 2024 vs. Q4 2023
How the institutions holding Avalo Therapeutics, Inc. changed between Q4 2023 and Q1 2024.
All holders in Q1 2024All holders in Q4 2023
| Measure | Q4 2023 | Q1 2024 | Change |
|---|---|---|---|
| Holders | 12 | 18 | +6 |
| Shares | 23.0K | 87.5K | +64.5K (+281.0%) |
| Value | $209.4K | $1.90M | +$1.69M (+806.5%) |
New holders (8)
Institutions that held Avalo Therapeutics, Inc. at the end of Q1 2024 but not at the end of Q4 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Ikarian Capital, LLC | 46,648 | $1.01M | 0.28% |
| Sio Capital Management, LLC | 10,151 | $220.8K | 0.08% |
| Affinity Asset Advisors, LLC | 10,000 | $217.5K | 0.04% |
| ADAR1 Capital Management, LLC | 6,000 | $130.5K | 0.04% |
| Banque Cantonale Vaudoise | 338 | $2.00K | 0.00% |
| BNP Paribas Arbitrage, SA | 4 | $87 | 0.00% |
| Old Point Trust & Financial Services N A | 1 | $22 | 0.00% |
| Parallel Advisors, LLC | 1 | $22 | 0.00% |
Sold out (2)
Institutions that held Avalo Therapeutics, Inc. at the end of Q4 2023 and filed for Q1 2024 without it.
| Institution | Shares, Q4 2023 | Value, Q4 2023 |
|---|---|---|
| FNY Investment Advisers, LLC | 522 | $4.00K |
| First Horizon Advisors, Inc. | 1 | $9 |